A new paradigm for immunoglobulin E in allergic diseases.
Recent observations at the level of the antigen presenting cell, as well as the T cell, point toward a pivotal role for interleukin (IL)-10 in the control of immunoglobulin E (IgE)-mediated allergic diseases, such as asthma and rhinitis. This has led to restructuring of the Th1/Th2 paradigm with IL-10 acting to modulate Th2-driven IgE antibody (Ab) responses. The modified Th2 response to cat allergen is associated with high-dose allergen exposure and the presence of high titer IgG and IgG4 Ab; however, IgE Ab and allergic symptoms are absent. Characteristics of this immune response indicate that it is a variant of the allergic response, which develops in an IL-10-dependent manner, but it is distinct from other types of nonallergic or tolerant responses. These observations point toward a new paradigm for the development of IgE-mediated responses. This may be important for advancing our understanding of the response to immunotherapy and anti-IgE, and for defining immune mechanisms that drive allergic responses.
Woodfolk
Judith A
JA
Asthma and Allergic Diseases Center, University of Virginia Health System, Charlottesville 22908-1355, USA. jaw4m@virginia.edu
D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D007073:Immunoglobulin E / Q000276:immunology*; D051379:Mice; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology*
D006023:Glycoproteins; D007073:Immunoglobulin E; C059296:Fel d 1 protein, Felis domesticus